Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab for prevention and treatment of EBV disease in pediatric transplant and primary immunodeficiency patients
2007-000468-26Phase 2Completed
- Sponsor
- IRCCS San Matteo Foundation
- Start
- May 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of rituximab in Epstein-Barr virus infection and Post-Transplant Lymphoproliferative Disorder (PTLD), sponsored by IRCCS San Matteo Foundation. Primary endpoint: PTLD incidence. Started May 2007; status: completed.
02
Drugs
rituximab
03
Conditions
Epstein-Barr virus infectionPost-Transplant Lymphoproliferative Disorder (PTLD)
Beyond the preview
Go deeper on 2007-000468-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000468-26.